Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04317040 · ClinicalTrials.gov registry record · Phase 3
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
A Phase 3 study, sponsored by Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT04317040 is a Phase 3 study that has completed, run by Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 234 participants.
The verdict
NCT04317040, a Phase 3 study, has completed, sponsored by Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support. The primary hypothesis of the study is clinical improvement in the experimental group versus the control group.
Interventions
- DRUG Placebo
- DRUG Efprezimod alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2020-10-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04317040
The ClinicalTrials.gov registry entry for NCT04317040 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04317040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04317040 about?
NCT04317040 is a clinical study titled "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)". This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support. The primary hypothesis of the study is clinical improvement in the experimental group versus the control group.
What is the current status of trial NCT04317040?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2020-04-24. Estimated completion is 2020-10-20.
What interventions are being tested in trial NCT04317040?
The interventions under investigation include: Placebo (DRUG), Efprezimod alfa (DRUG).
Who is sponsoring clinical trial NCT04317040?
This trial is sponsored by Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.